Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Skin and Connective Tissue Diseases

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44394   clinical trials with a EudraCT protocol, of which   7406   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,108 result(s) found for: Skin and Connective Tissue Diseases. Displaying page 26 of 56.
    «« First « Previous 22  23  24  25  26  27  28  29  30  Next» Last»»
    EudraCT Number: 2011-003836-29 Sponsor Protocol Number: R668-AD-1117 Start Date*: 2012-02-28
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: A randomized, double-blind, placebo-controlled, repeat-dose study of the efficacy, safety, tolerability, and pharmacodynamics of subcutaneously-administered REGN668 in adult patients with extrinsic...
    Medical condition: Atopic Dermatitis
    Disease: Version SOC Term Classification Code Term Level
    15.0 10040785 - Skin and subcutaneous tissue disorders 10003639 Atopic dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2019-000122-21 Sponsor Protocol Number: M16-833 Start Date*: 2019-08-23
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Risankizumab in Adult Subjects with Moderate to Severe Hidradenitis Suppurativa
    Medical condition: Hidradenitis Suppurativa
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10020041 Hidradenitis suppurativa LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) NL (Prematurely Ended) FR (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-004284-98 Sponsor Protocol Number: CAIN457A02001B Start Date*: Information not available in EudraCT
    Sponsor Name:Novartis Pharma AG
    Full Title: An open-label, multi-center protocol for patients who have completed a previous Novartis sponsored Secukinumab study and are judged by the investigator to benefit from continued Secukinumab treatment
    Medical condition: Psoriatic Arthritis, Ankylosing Spondylitis, non-radiographic axial spondyloarthritis, Severe Chronic Plaque Psoriasis, moderate to severe chronic plaque psoriasis
    Disease: Version SOC Term Classification Code Term Level
    21.0 10028395 - Musculoskeletal and connective tissue disorders 10037160 Psoriatic arthritis LLT
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10002556 Ankylosing spondylitis PT
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10076297 Non-radiographic axial spondyloarthritis LLT
    20.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Trial now transitioned) PL (Trial now transitioned) BG (Trial now transitioned) GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-005569-38 Sponsor Protocol Number: CLS003-CO-PR-001 Start Date*: 2014-02-17
    Sponsor Name:Cutanea Life Sciences
    Full Title: A phase I/IIa open-label First-in-Human study to assess safety and pharmacokinetics and explore biomarker effects of topical ionic contra-viral therapy (ICVT) comprised of digoxin and furosemide in...
    Medical condition: Cutaneous warts
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004862 10033724 Papilloma viral infections HLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-004886-98 Sponsor Protocol Number: TOC110978 Start Date*: 2017-01-24
    Sponsor Name:GlaxoSmithKline
    Full Title: A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, versus Oral Linezolid in the Treatment of Secondarily...
    Medical condition: secondarily-infected traumatic lesions (SITL; excluding abscesses) or impetigo due to methicillin-resistant Staphylococcus aureus (MRSA
    Disease: Version SOC Term Classification Code Term Level
    19.1 10021881 - Infections and infestations 10021531 Impetigo PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2010-024005-13 Sponsor Protocol Number: 3098009 Start Date*: 2011-03-11
    Sponsor Name:Orion Corporation Orion Pharma
    Full Title: Efficacy of ORM-12741 for prevention of cold-induced vasospasm; a randomised, double-blind, placebo-controlled, single centre crossover study in patient with Raynaud's phenomenon secondary to syste...
    Medical condition: Raynaud's phenomenon secondary to systemic sclerosis (Raynaud's syndrome)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10047065 - Vascular disorders 10037914 Raynaud's syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-000023-33 Sponsor Protocol Number: PIR-BO-11-001 Start Date*: 2011-11-02
    Sponsor Name:S.P.A. ITALIANA LABORATORI BOUTY
    Full Title: Clinical trial to evaluate, in patient suffering of neck pain the therapeutic equivalence, tolerability and satisfaction of subjects treated by medicated plaster containing piroxicam or diclofenac.
    Medical condition: cervical pain of osteoarthritic origin
    Disease: Version SOC Term Classification Code Term Level
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10008322 Cervicalgia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-002128-28 Sponsor Protocol Number: STS-CSM-1/13 Start Date*: 2015-03-02
    Sponsor Name:Dr. F. Köhler Chemie GmbH
    Full Title: A Prospective Multicenter Phase 2/3 Clinical Trial with Sodium Thiosulfate for the Treatment of Calciphylaxis
    Medical condition: Calciphylaxis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10051714 Calciphylaxis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-003298-32 Sponsor Protocol Number: I6T-MC-AMAK Start Date*: 2018-07-10
    Sponsor Name:Eli Lilly and Company
    Full Title: A Multicenter Study with a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Withdrawal Maintenance Dosing Period to Evaluate the Efficacy and Safety of ...
    Medical condition: Moderate to Severe Plaque Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2016-004782-11 Sponsor Protocol Number: 2002C014G Start Date*: 2017-12-05
    Sponsor Name:Prometic Biotherapeutics Ltd
    Full Title: A Phase 1/2A Prospective, Dose-Escalation, Open-Label Study of the Safety, Feasibility, and Initial Efficacy of Subcutaneous Plasminogen (Human) 10 for the Treatment of Diabetic Foot Ulcer
    Medical condition: Diabetic foot ulcer (DFU)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000014568 10012664 Diabetic foot ulcer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-001716-30 Sponsor Protocol Number: CRC-ACNE-AC-04 Start Date*: 2013-09-23
    Sponsor Name:Clinical Research Center for Hair and Skin Science
    Full Title: Exploratory, controlled, randomized, observer-blind intrainidividual clinical trial to evaluate the efficacy and the tolerability of topically applied 0.1% tyrothricin (Tyrosur® Gel) in patients wi...
    Medical condition: MILD TO SEVERE PAPULOPUSTULAR ACNE
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004858 10000519 Acne vulgaris LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-004542-28 Sponsor Protocol Number: NL59862.091.16 Start Date*: 2017-09-14
    Sponsor Name:Radboud University Medical Center
    Full Title: A randomized controlled pilot study comparing the efficacy of topical coal tar to topical corticosteroids in children aged 1 to < 16 years with moderate-severe atopic dermatitis.
    Medical condition: Atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-004687-19 Sponsor Protocol Number: NL59928.091.16 Start Date*: 2018-04-23
    Sponsor Name:Radboud University Medical Center
    Full Title: A randomized controlled trial evaluating the additional effect of topical coal tar to a topical corticosteroid regimen in patients aged >16 years of age with moderate-severe atopic dermatitis.
    Medical condition: Atopic Dermatitis (AD)
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-002203-34 Sponsor Protocol Number: M16-813 Start Date*: 2021-04-28
    Sponsor Name:AbbVie Deutschland
    Full Title: A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Risankizumab in Adult and Adolescent Subjects with Moderate to Severe Atopic Dermatitis
    Medical condition: Atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-002663-42 Sponsor Protocol Number: TFDTRASP Start Date*: 2015-11-13
    Sponsor Name:Clínica Universidad de Navarra/Universidad de Navarra
    Full Title: RANDOMISED PILOT STUDY TO ASSESS THE CLINICAL EFFICACY OF DAYLIGHT PHOTODYNAMIC THERAPY WITH METHYL AMINOLEVULINATE CREAM (METVIX?), (MAL-PDT), IN THE PREVENTION OF ACTINIC KERATOSIS AND NON MELANO...
    Medical condition: Actinic Keratosis (AK) are histologically characterized by the proliferation of keratinocytes with atypical cytology in the epidermis. One of the main risk factors for its occurrence is immunosuppr...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2011-005037-39 Sponsor Protocol Number: KEKLUKACS-CLIN-01 Start Date*: 2012-04-17
    Sponsor Name:Lukács és Társa Gyógyszerkereskedelmi Betéti Társaság
    Full Title: A Phase II Randomized, Controlled Parallel-Group Pilot Study to Assess the Safety and Efficacy of Kék Lukács Ointment Compared to Standard Silver Sulphadiazine (Dermazin®, SSD) Therapy in the Wound...
    Medical condition: Patients with burn injuries confined to the trunk and/or upper and lower extremities. Total burn area for all burns on a single patient should be no greater than 15% of TBSA. Patients’ total study ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-002988-33 Sponsor Protocol Number: IFX-1-P2.3 Start Date*: 2016-11-04
    Sponsor Name:InflaRx GmbH
    Full Title: An open label Phase II trial to evaluate the safety of IFX-1 in patients with moderate to severe Hidradenitis suppurativa
    Medical condition: Hidradenitis suppurativa
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004858 10020041 Hidradenitis suppurativa LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: View results
    EudraCT Number: 2020-003476-41 Sponsor Protocol Number: ANB019-206 Start Date*: 2021-07-17
    Sponsor Name:AnaptysBio Inc.
    Full Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ANB019 in the Treatment of Subjects with Ichthyosis
    Medical condition: Ichthyosis
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004858 10037159 Psoriasis pustular LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-001098-34 Sponsor Protocol Number: I6T-MC-AMAF Start Date*: 2016-10-31
    Sponsor Name:Eli Lilly and Company
    Full Title: Protocol I6T-MC-AMAF A Phase 2, Multicenter, Randomized, Parallel-arm, Placebo-Controlled Study of LY3074828 in Subjects with Moderate to Severe Plaque Psoriasis
    Medical condition: Moderate to Severe Plaque Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2020-004194-51 Sponsor Protocol Number: 020520 Start Date*: Information not available in EudraCT
    Sponsor Name:Medical University of Lodz
    Full Title: A prospective, randomized, phase III open-label clinical trial with blinded end-point assessment to evaluate the efficacy and safety of cyclosporine and methotrexate in children and adolescent subj...
    Medical condition: Atopic dermatitis
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: PL (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 22  23  24  25  26  27  28  29  30  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 28 19:36:31 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA